- Open
- 43.00
- High
- 44.00
- Low
- 42.00
- Close
- 42.55
- Change
- -1.00 (-2.33%)
- Volume
- 148,800
| 30 Mar 2026 | 07:30:00 | Suspension - Faron Pharmaceuticals Oy |
| 3 Mar 2025 | 12:05:33 | FDA Grants Orphan Drug Designation |
| 28 Feb 2025 | 12:00:00 | Notice of Annual General Meeting |
| 27 Feb 2025 | 07:30:00 | Positive EMA Opinion on Orphan Drug Designation |
| 27 Feb 2025 | 07:15:01 | Annual Report 2024 published |
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat cancers. Its lead product, bexmarilimab, is an investigational humanized antibody designed to target the Clever-1 receptor on macrophages, aiming to reprogram myeloid cell function and enhance immune responses against tumors. Faron conducts clinical trials for bexmarilimab in combination with standard treatments for hematological malignancies, including acute myeloid leukemia and myelodysplastic syndrome. The company operates globally, seeking to expand the accessibility of immunotherapy for cancer patients.
| 30 Mar 2026 | 07:30:00 | Suspension - Faron Pharmaceuticals Oy |
| 3 Mar 2025 | 12:05:33 | FDA Grants Orphan Drug Designation |
| 28 Feb 2025 | 12:00:00 | Notice of Annual General Meeting |
| 27 Feb 2025 | 07:30:00 | Positive EMA Opinion on Orphan Drug Designation |
| 27 Feb 2025 | 07:15:01 | Annual Report 2024 published |
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat cancers. Its lead product, bexmarilimab, is an investigational humanized antibody designed to target the Clever-1 receptor on macrophages, aiming to reprogram myeloid cell function and enhance immune responses against tumors. Faron conducts clinical trials for bexmarilimab in combination with standard treatments for hematological malignancies, including acute myeloid leukemia and myelodysplastic syndrome. The company operates globally, seeking to expand the accessibility of immunotherapy for cancer patients.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £203.46bn | +0.2% | |
| £86.22bn | +0.5% | |
| £1.51bn | -0.3% | |
| £42m | +3.2% | |
| £27m | +1.2% | |
FARNFaron Pharmaceuticals OY | £23m | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £203.46bn | +0.2% | |
| £86.22bn | +0.5% | |
| £1.51bn | -0.3% | |
| £42m | +3.2% | |
| £27m | +1.2% | |
FARNFaron Pharmaceuticals OY | £23m | -0.8% |
